# US 2019/0315644 A1 · Continous ion exchange radium complexing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315644 A1
- Document ID: US20190315644A1
- Status: Published application
- Kind: A1
- Application number: 16/384,734
- Filed: 2019-04-15
- Published: 2019-10-17
- Earliest claimed: 2018-04-16
- Applicants: Inventure Renewables, Inc.
- Inventors: William Rusty SUTTERLIN; Christopher CHECK; William W. BERRY
- Web page: https://patentgrep.com/patent/US20190315644A1

## CPC

- C02F 9/00: Multistage treatment of water, waste water or sewage
- G21F 9/12: by absorption; by adsorption; by ion-exchange
- C02F 1/42: by ion-exchange (ion-exchange in general B01J)
- C02F 2001/425: {using cation exchangers}
- C02F 2101/006: {Radioactive compounds}
- C02F 2101/10: Inorganic compounds
- C02F 2103/10: from quarries or from mining activities
- C02F 2301/08: Multistage treatments, e.g. repetition of the same process step under different conditions
- C02F: TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE (separation in general B01D; special arrangements on waterborne vessels of installations for treating water, waste water or sewage, e.g. for producing fresh water, B63J; adding materials to water to prevent corrosion C23F; treating radioactively-contaminated liquids G21F9/04; regeneration of reactants for recirculation into processes, see the relevant places for the processes)
- G21F: PROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR (radiation protection by pharmaceutical means A61K8/00, A61Q17/04; in cosmonautic vehicles B64G1/54; combined with a reactor G21C11/00; combined with X-ray tubes H01J35/16; combined with X-ray apparatus H05G1/02)

## Abstract

In alternative embodiments, provided are methods and industrial processes for treating radium-containing oil well flow-back to produce a completely or substantially radium-free water stream product. In alternative embodiments, provided are methods and industrial processes comprising contacting an oil well flow-back with an ion exchange compound to completely or substantially remove radium from the effluent water stream, thereby producing a completely or substantially radium-free effluent, or product. In alternative embodiments, methods provided herein remove the radium present in radium-containing fluids, and the resultant effluents can be removed and stabilized. In alternative embodiments, methods and systems are provided herein are applicable to the treatment of effluents from the hydraulic fracturing of oil and gas formations.

## Claims

### Claim 1

A method or process for the removal of radium or radium ions and minor element components from a frac water or a primary frac water solution which comprises radium or radium ions, and optionally also comprises a minor element component, wherein a minor element component comprises any of barium, iron, aluminum and magnesium, the method or process comprising use of a calcium sulfate ion exchange compound in combination with, or in conjunction with, a Continuous Ion Exchange (CIX) system or continuous liquid solid contacting system.

### Claim 2 (depends on 1)

The method or process of claim 1, wherein a cation compound is used to remove the radium or radium ions from the frac water and load the radium ions onto a strong cation ion exchange compound, wherein optionally the strong cation exchange compound comprises a sulfate or a sulfite form to conduct the removal step.

### Claim 3 (depends on 1)

The method or process of claim 1, wherein the primary frac water solution is contacted with a first ion exchange compound comprising a complexing compound with affinity for radium or radium ions from a frac water media, thereby producing a secondary frac water solution.

### Claim 4 (depends on 3)

The method or process of claim 3, wherein the secondary frac water solution is contacted with a second ion exchange compound comprising a complexing compound with affinity for radium or radium ions from a frac water media, thereby producing a tertiary frac water solution.

### Claim 5 (depends on 4)

The method or process of claim 4, wherein the tertiary frac water solution is contacted with a third ion exchange compound comprising a complexing compound with affinity for radium or radium ions from a frac water media, thereby producing a quaternary frac water solution.

### Claim 6 (depends on 1)

A method or process of claim 1, wherein the Continuous Ion Exchange (CIX) system or the continuous liquid solid contacting system comprises any one or several of:
Agarose, 4% cross-linked, hardened (e.g., an SP Cellthru BigBead Plus™ (Sterogene, Carlsbad, Calif.)),
Agarose, 6% cross-inked, quartz core (e.g., a Streamline SP™ (GE Healthcare Life Sciences)),
Agarose, 6% cross-linked, quartz core, dextran surface extender (e.g., a Streamline SP XL™ (GE Healthcare Life Sciences)),
Agarose, 6% cross-linked (e.g., SP Sepharose Big Beads™ (GE Healthcare Life Sciences)),
Methacrylic polymer (e.g., a Toyopearl M-Cap II SP-550EC™ (Tosoh Bioscience, King of Prussia, Pa.)),
Dextran, cross-linked (e.g., an SP Sephadex A-25™ (GE Healthcare Life Sciences)),
Methacrylic polymer (e.g., a Toyopearl SP-550C™) (Tosoh Bioscience, King of Prussia, Pa.)),
Methacrylic polymer (e.g., a Toyopearl SP-650C™) (Tosoh Bioscience, King of Prussia, Pa.)),
Agarose, 6% crosslinked (e.g., a SP Sepharose Fast Flow™ (GE Healthcare Life Sciences)),
Agarose, 6% cross-linked, dextran surface extender (e.g., a SP Sepharose XL™ (GE Healthcare Life Sciences)),
Cellulose, cross-linked, dextran surface extender (e.g., a Cellufine MAX 5-r™ (JNC Corporation, JP),
Acrylamide/vinyl copolymer, proprietary surface extender (e.g., a Nuvia S™ (BioRAD),
Vinyl ether polymer, proprietary surface extender (e.g., a Eshmuno S Resin™ (Millipore),
Acrylamide/vinyl copolymer (e.g., a UNOsphere S™ (BioRAD),
Methacrylic polymer (e.g., a Toyopearl Giga-Cap S-650 (M)™) (Tosoh Bioscience, King of Prussia, Pa.)),
Acrylamide-dextran copolymer (e.g., a MacroCap SP™ (GE Healthcare Life Sciences)),
Methacrylic polymer (e.g., a Toyopearl SP-650S™ (Tosoh Bioscience, King of Prussia, Pa.)), and/or
Methacrylic polymer (e.g., a TSKgel SP-3PW™ (Tosoh Bioscience, King of Prussia, Pa.)).

### Claim 7

A method or process for removing a radium radioactive material from water or an aqueous solution, the method comprising:
(a) contacting a radium containing water or an aqueous solution, optionally a frac water, with a solid ion exchange compound comprising a calcium sulfate, a calcium sulfite or a mixture thereof, thereby producing a radium sulfate, radium sulfite or a combination thereof within the solid ion exchange compound; and
(b) separating the treated water or aqueous solution from the solid ion exchange compound and the radium-exchanged radium sulfate, radium sulfite or a combination thereof.

### Claim 8 (depends on 7)

The method or process of claim 7, wherein the calcium sulfate is in a powder form.

### Claim 9 (depends on 7)

The method or process of claim 7, wherein the calcium sulfate is in a granular form.

### Claim 10 (depends on 7)

The method or process of claim 7, wherein the calcium sulfate ion exchange compound is used in combination with, or in conjunction with, a Continuous Ion Exchange (CIX) system or continuous liquid solid contacting system.

### Claim 11 (depends on 7)

The method or process of claim 7, wherein the calcium sulfate ion exchange compound is used in combination with, or in conjunction with, a Continuous Ion Exchange (CIX) system or continuous liquid solid contacting system.

### Claim 12

A method or process for removing barium and a naturally occurring radioactive material from water or an aqueous solution, the method comprising:
(a) treating the water or aqueous solution by adding a mixture comprising a substantially calcium sulfate and calcium sulfite source to form a suspension of barium sulfite, radium sulfite, barium sulfate, radium sulfate or a combination thereof; and
(b) separating the treated water or aqueous solution from the barium sulfite, radium sulfite, barium sulfate, radium sulfate or combination thereof.

### Claim 13 (depends on 12)

The method or process of claim 12, wherein the sulfite and/or sulfate source is in a powder form.

### Claim 14 (depends on 12)

The method or process of claim 12, wherein the sulfite and/or sulfate source is in a granular form.

### Claim 15 (depends on 12)

The method or process of claim 12 wherein the separation of the substantially barium and radium sulfite salt and barium and radium sulfate salt is done by gravity or centrifugation, optionally by use of a hydrocyclone.

### Claim 16 (depends on 12)

The method or process of claim 12, wherein the separation of the substantially barium and radium sulfite salt and barium and radium sulfate salt is done by a filtration or by cyclonic separation,
wherein optionally the filtration system comprises a leaf filter, a filter press, a membrane filter, a canister filter or a sock filter.

### Claim 17 (depends on 12)

A method or process of claim 12, wherein the method or process is carried out under conditions comprising between about pH 6 and pH 9, between about pH 5 and pH 10, or between about pH 4 and pH 11.

### Claim 18 (depends on 12)

A method or process of claim 12, wherein the Continuous Ion Exchange (CIX) system or the continuous liquid solid contacting system comprises any one or several of:
Agarose, 4% cross-linked, hardened (e.g., an SP Cellthru BigBead Plus™ (Sterogene, Carlsbad, Calif.)),
Agarose, 6% cross-inked, quartz core (e.g., a Streamline SP™ (GE Healthcare Life Sciences)),
Agarose, 6% cross-linked, quartz core, dextran surface extender (e.g., a Streamline SP XL™ (GE Healthcare Life Sciences)),
Agarose, 6% cross-linked (e.g., SP Sepharose Big Beads™ (GE Healthcare Life Sciences)),
Methacrylic polymer (e.g., a Toyopearl M-Cap II SP-550EC™ (Tosoh Bioscience, King of Prussia, Pa.)),
Dextran, cross-linked (e.g., an SP Sephadex A-25™ (GE Healthcare Life Sciences)),
Methacrylic polymer (e.g., a Toyopearl SP-550C™) (Tosoh Bioscience, King of Prussia, Pa.)),
Methacrylic polymer (e.g., a Toyopearl SP-650C™) (Tosoh Bioscience, King of Prussia, Pa.)),
Agarose, 6% crosslinked (e.g., a SP Sepharose Fast Flow™ (GE Healthcare Life Sciences)),
Agarose, 6% cross-linked, dextran surface extender (e.g., a SP Sepharose XL™ (GE Healthcare Life Sciences)),
Cellulose, cross-linked, dextran surface extender (e.g., a Cellufine MAX 5-r™ (JNC Corporation, JP),
Acrylamide/vinyl copolymer, proprietary surface extender (e.g., a Nuvia S™ (BioRAD),
Vinyl ether polymer, proprietary surface extender (e.g., a Eshmuno S Resin™ (Millipore),
Acrylamide/vinyl copolymer (e.g., a UNOsphere S™ (BioRAD),
Methacrylic polymer (e.g., a Toyopearl Giga-Cap S-650 (M)™) (Tosoh Bioscience, King of Prussia, Pa.)),
Acrylamide-dextran copolymer (e.g., a MacroCap SP™ (GE Healthcare Life Sciences)),
Methacrylic polymer (e.g., a Toyopearl SP-650S™ (Tosoh Bioscience, King of Prussia, Pa.)), and/or
Methacrylic polymer (e.g., a TSKgel SP-3PW™ (Tosoh Bioscience, King of Prussia, Pa.)).
